Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06488742 · ClinicalTrials.gov registry record · NA
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
A NA study of Dermatitis, Atopic and Pruritus, sponsored by Nexgen Dermatologics.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06488742 is a NA study of Dermatitis, Atopic and Pruritus that is actively recruiting participants, run by Nexgen Dermatologics. The registered enrollment target is 60 participants, below the 395-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06488742, a NA study of Dermatitis, Atopic and Pruritus, is actively recruiting participants, sponsored by Nexgen Dermatologics.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Atopic dermatitis is a common disease affecting millions worldwide. A common associated symptom in this population is pruritus. We seek to investigate the use of an natural, over-the-counter cosmeceutical to help this population
Conditions Studied
Interventions
- OTHER 3% kanuka oil
Study Locations (1)
Florida
- Berlin Center - Boynton Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2025-03-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06488742
The ClinicalTrials.gov registry entry for NCT06488742 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 395-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (85% lower). The listed sponsor is Nexgen Dermatologics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Dermatitis, Atopic appearing as the primary indexed condition, and to 1 intervention - of which 3% kanuka oil is the first listed.
NCT06488742 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06488742 about?
NCT06488742 is a clinical study titled "The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis". Atopic dermatitis is a common disease affecting millions worldwide. A common associated symptom in this population is pruritus. We seek to investigate the use of an natural, over-the-counter cosmeceutical to help this population
What is the current status of trial NCT06488742?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2023-11-01. Estimated completion is 2025-03-20.
What conditions does trial NCT06488742 study?
This clinical trial studies the following conditions: Dermatitis, Atopic, Pruritus.
What interventions are being tested in trial NCT06488742?
The interventions under investigation include: 3% kanuka oil (OTHER).
Who is sponsoring clinical trial NCT06488742?
This trial is sponsored by Nexgen Dermatologics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06488742 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Therapeutic Patient Education for Atopic Dermatitis: Evaluation of a Parent Handbook
COMPLETED · NA
-
A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area
COMPLETED · NA
-
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
RECRUITING
-
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.